PCSK9 and familial hyperaldosteronism: In the SAFEHEART registry, roughly 5% and 22% of patients achieved LDL-C < 70 and < 100 mg/dL, respectively.41 Monoclonal PCSK9 inhibitors may add 50% to 55% additional LDL-C lowering for individuals with severe heterozygous and 22% for those with homozygous FH.9 In a recent evaluation from the same SAFEHEART cohort, the addition of PCSK9 inhibitors on top of usual therapy helped 67% of patients attain LDL-C < 70 mg/dL and 80% attain LDL-C < 100 mg/dL.42 In those considered to be at very high-risk, LDL-C < 55 mg/dL was attained in 46% of the cases.